Cannabidiol Promotes Neuronal Differentiation Using Akt and Erk Pathways Triggered by Cb1 Signaling.
Santino BlandoIvana RaffaeleLuigi ChiricostaAndrea ValeriAgnese GugliandoloSerena SilvestroFederica PollastroEmanuela MazzonPublished in: Molecules (Basel, Switzerland) (2022)
Recently, the scientific community has started to focus on the neurogenic potential of cannabinoids. The phytocompound cannabidiol (CBD) shows different mechanism of signaling on cannabinoid receptor 1 (CB1), depending on its concentration. In this study, we investigated if CBD may induce in vitro neuronal differentiation after treatment at 5 µM and 10 µM. For this purpose, we decided to use the spinal cord × neuroblastoma hybrid cell line (NSC-34) because of its proliferative and undifferentiated state. The messenger RNAs (mRNAs) expression profiles were tested using high-throughput sequencing technology and Western blot assay was used to determine the number of main proteins in different pathways. Interestingly, the treatment shows different genes associated with neurodifferentiation statistically significant, such as Rbfox3,   Tubb3 , Pax6 and Eno2 . The CB1 signaling pathway is responsible for neuronal differentiation at 10 µM, as suggested by the presence of p-ERK and p-AKT, but not at 5 µM. A new correlation between CBD, neurodifferentiation and retinoic acid receptor-related orphan receptors (RORs) has been observed.
Keyphrases
- signaling pathway
- pi k akt
- spinal cord
- cell proliferation
- high throughput sequencing
- induced apoptosis
- spinal cord injury
- epithelial mesenchymal transition
- cerebral ischemia
- mental health
- healthcare
- south africa
- protein kinase
- risk assessment
- neuropathic pain
- brain injury
- oxidative stress
- atomic force microscopy
- blood brain barrier
- replacement therapy
- single molecule
- subarachnoid hemorrhage
- genome wide analysis